Biomea Fusion, Inc. (BMEA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Redwood City, CA, 美国. 现任CEO为 Michael J. Hitchcock.
BMEA 拥有 IPO日期为 2021-04-16, 79 名全职员工, 在 NASDAQ Global Select, 市值为 $116.02M.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
